Company profile: Levicept
1.1 - Company Overview
Company description
- Provider of biological therapies for chronic pain, including LEVI-04 (p75NTR-Fc) for knee osteoarthritis that modulates the neurotrophin pathway to minimize side effects associated with anti-NGF antibodies, and a Phase II randomized, double-blind, placebo-controlled clinical trial assessing its efficacy, safety, and tolerability.
Products and services
- Biological Agent Development for Chronic Pain: Levicept architects biological analgesics to treat chronic pain, aiming to meet the unmet need for safer, effective pain management given NSAID adverse-effect limitations
- LEVI-04 (p75NTR-Fc): An Fc-fusion biological therapy engineered to modulate the neurotrophin pathway and minimize anti-NGF antibody-associated side effects in knee osteoarthritis pain management
- Phase II Clinical Trial of LEVI-04: A randomized, double-blind, placebo-controlled Phase II study evaluating efficacy, safety, and tolerability of LEVI-04 in patients with knee osteoarthritis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Levicept
Adamas Pharma
HQ: United States
Website
- Description: Provider of controlled and extended-release combination therapeutics for infectious diseases and central nervous system disorders, including products for symptomatic treatment of dementia. Offerings include Qelbree for ADHD; Trokendi XR and Oxtellar XR for epilepsy and migraine prevention; and candidates SPN-830 (hypomobility in Parkinson’s disease), SPN-820/821 (treatment-resistant depression), SPN-817 (severe epilepsy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adamas Pharma company profile →
Rodin Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for neurological disorders by applying insights of epigenetics, leveraging key epigenetic modulators of CNS function and privileged access to Proteros’ best-in-class structural biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rodin Therapeutics company profile →
Lexeo Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy candidates for genetically defined cardiovascular and CNS diseases, including LX2006 for cardiac Friedreich’s ataxia (frataxin), LX2020 for arrhythmogenic cardiomyopathy (PKP2), LX2021 for desmoplakin cardiomyopathy and certain forms of dilated cardiomyopathy (connexin 43), LX2022 for hypertrophic cardiomyopathy (TNNI3), and CNS APOE2 programs for APOE4 homozygous Alzheimer’s (LX1001, LX1020).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexeo Therapeutics company profile →
Caraway Therapeutics
HQ: United States
Website
- Description: Provider of precision small-molecule therapeutics for CNS and rare diseases, developing medicines that enhance cellular clearance by activating the lysosome to remove toxic materials and defective cellular components. Leverages modulation of mitophagy and autophagy to use natural clearance pathways, preventing cell damage and treating neurodegenerative disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caraway Therapeutics company profile →
Eleusian Biosciences
HQ: Canada
Website
- Description: Provider of therapeutics in development for multiple pathological psychological diseases, based on psilocybin plus N-acetylcysteine (NAC) compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleusian Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Levicept
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Levicept
2.2 - Growth funds investing in similar companies to Levicept
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Levicept
4.2 - Public trading comparable groups for Levicept
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →